APA (7th ed.) Citation

JS, J., JW, M., F, H., MJ, S., X, Y., G, R. S., . . . J, C. (2026). Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: Six-year survival outcomes and molecular signatures from a phase 2 trial. Nature communications, 17(1), . https://doi.org/10.1038/s41467-026-73336-1

Chicago Style (17th ed.) Citation

JS, Johnson, et al. "Pembrolizumab Plus High-dose IL-2 in Advanced Clear Cell Renal Cell Carcinoma: Six-year Survival Outcomes and Molecular Signatures from a Phase 2 Trial." Nature Communications 17, no. 1 (2026). https://doi.org/10.1038/s41467-026-73336-1.

MLA (9th ed.) Citation

JS, Johnson, et al. "Pembrolizumab Plus High-dose IL-2 in Advanced Clear Cell Renal Cell Carcinoma: Six-year Survival Outcomes and Molecular Signatures from a Phase 2 Trial." Nature Communications, vol. 17, no. 1, 2026, https://doi.org/10.1038/s41467-026-73336-1.